INTRODUCTION: Improving fat absorption remains a challenge in cystic fibrosis (CF). Antibiotics (AB) treatment has been shown to improve body weight in CF mice. The mechanism may include improvement in fat absorption. We aimed to determine the effect of AB on fat absorption in two CF mouse models. RESULTS: AB did not improve total fat absorption. Interestingly, AB accelerated the absorption of isotope-labeled fats, in both Δ/Δ and WT mice. The changes observed were not related to the solubilization capacity of bile or to changes in the bacteria in the small intestine. AB reduced the fecal excretion of cholate by ~50% (P < 0.05) in both CF mouse models, indicating improved intestinal bile salt absorption. DISCUSSION: In conclusion, AB treatment does not improve total fat absorption in CF mice but does decrease fecal loss of bile salts and accelerate long-chain fatty acid (LCFA) absorption. METHODS: For 3 weeks, we administered oral AB (ciprofloxacin/metronidazole) or control treatment to homozygous ΔF508 (Δ/Δ), cystic fibrosis transmembrane conductance regulator (CFTR) knockout (-/-), and wild-type (WT) mice and quantified fat absorption using a 72-h fat balance test. In Δ/Δ mice, we assessed fat absorption kinetics by administering tri-1-(13)C-palmitin and 1-(13)C-stearate intragastrically and determining the appearance of stable isotope-labeled fats in plasma. We quantified biliary and fecal bile salts (gas chromatography) and small intestinal bacteria (quantitative-PCR).
INTRODUCTION: Improving fat absorption remains a challenge in cystic fibrosis (CF). Antibiotics (AB) treatment has been shown to improve body weight in CF mice. The mechanism may include improvement in fat absorption. We aimed to determine the effect of AB on fat absorption in two CF mouse models. RESULTS: AB did not improve total fat absorption. Interestingly, AB accelerated the absorption of isotope-labeled fats, in both Δ/Δ and WT mice. The changes observed were not related to the solubilization capacity of bile or to changes in the bacteria in the small intestine. AB reduced the fecal excretion of cholate by ~50% (P < 0.05) in both CF mouse models, indicating improved intestinal bile salt absorption. DISCUSSION: In conclusion, AB treatment does not improve total fat absorption in CF mice but does decrease fecal loss of bile salts and accelerate long-chain fatty acid (LCFA) absorption. METHODS: For 3 weeks, we administered oral AB (ciprofloxacin/metronidazole) or control treatment to homozygous ΔF508 (Δ/Δ), cystic fibrosis transmembrane conductance regulator (CFTR) knockout (-/-), and wild-type (WT) mice and quantified fat absorption using a 72-h fat balance test. In Δ/Δ mice, we assessed fat absorption kinetics by administering tri-1-(13)C-palmitin and 1-(13)C-stearate intragastrically and determining the appearance of stable isotope-labeled fats in plasma. We quantified biliary and fecal bile salts (gas chromatography) and small intestinal bacteria (quantitative-PCR).
Authors: Drucy Borowitz; Peter R Durie; Lane L Clarke; Steven L Werlin; Christopher J Taylor; John Semler; Robert C De Lisle; Peter Lewindon; Steven M Lichtman; Maarten Sinaasappel; Robert D Baker; Susan S Baker; Henkjan J Verkade; Mark E Lowe; Virginia A Stallings; Morteza Janghorbani; Ross Butler; James Heubi Journal: J Pediatr Gastroenterol Nutr Date: 2005-09 Impact factor: 2.839
Authors: Marcel J C Bijvelds; Inez Bronsveld; Rick Havinga; Maarten Sinaasappel; Hugo R de Jonge; Henkjan J Verkade Journal: Am J Physiol Gastrointest Liver Physiol Date: 2004-11-04 Impact factor: 4.052
Authors: H J Verkade; W A van Asselt; R J Vonk; C M Bijleveld; J Fernandes; H de Jong; V Fidler; A Okken Journal: Eur J Pediatr Date: 1989-11 Impact factor: 3.183
Authors: Maria van der Sluis; Monique H M Melis; Nicolas Jonckheere; Marie-Paule Ducourouble; Hans A Büller; Ingrid Renes; Alexandra W C Einerhand; Isabelle Van Seuningen Journal: Biochem Biophys Res Commun Date: 2004-12-17 Impact factor: 3.575
Authors: François-Pierre J Martin; Marc-Emmanuel Dumas; Yulan Wang; Cristina Legido-Quigley; Ivan K S Yap; Huiru Tang; Séverine Zirah; Gerard M Murphy; Olivier Cloarec; John C Lindon; Norbert Sprenger; Laurent B Fay; Sunil Kochhar; Peter van Bladeren; Elaine Holmes; Jeremy K Nicholson Journal: Mol Syst Biol Date: 2007-05-22 Impact factor: 11.429
Authors: Frank A J A Bodewes; Marcel J Bijvelds; Willemien de Vries; Juul F W Baller; Annette S H Gouw; Hugo R de Jonge; Henkjan J Verkade Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240
Authors: Marcela Doktorova; Irene Zwarts; Tim van Zutphen; Theo H van Dijk; Vincent W Bloks; Liesbeth Harkema; Alain de Bruin; Michael Downes; Ronald M Evans; Henkjan J Verkade; Johan W Jonker Journal: Sci Rep Date: 2017-04-12 Impact factor: 4.379
Authors: Pauline T Ikpa; Marcela Doktorova; Kelly F Meijsen; Natascha D A Nieuwenhuijze; Henkjan J Verkade; Johan W Jonker; Hugo R de Jonge; Marcel J C Bijvelds Journal: Cell Mol Gastroenterol Hepatol Date: 2019-08-27